Picture of Cann logo

CAN — Cann News Story

0.000.00%
au flag iconLast trade - 00:00
HealthcareHighly SpeculativeMicro CapTurnaround

Brief: Cann Group Announces Preliminary Results From Their Phase 3 Clinical Trial

Jan 19 (Reuters) - Cann Group Ltd  CAN.AX :
    * EXPECTS TRIAL RESULTS WILL DELAY SUBMISSION OF
REGISTRATION
APPLICATION TO THERAPEUTIC GOODS ADMINISTRATION FOR THIS
INDICATION
    * PRELIMINARY VIEW OF ANALYSIS OF PRIMARY END-POINTS HAVE
NOT
SHOWN A STATISTICALLY SUPERIOR RESPONSE COMPARED TO PLACEBO FOR
SATIPHARM

Source text for Eikon:  ID:nASX6Mz404 
Further company coverage:  CAN.AX 
 ((Reuters.Briefs@thomsonreuters.com;))

Recent news on Cann

See all news